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Abstract
Animal models of lymphoma should reflect their coun-
terparts in humans; however, it can be difficult to as-
certain whether an induced disease is intralymphatic
or extralymphatic based on direct visualization. Current
imaging methods are insufficient for identifying lym-
phatic and intralymphatic involvement. To differenti-
ate intralymphatic fromextralymphatic involvement, we
have developed a magnetic resonance imaging–based
lymphangiography method and tested it on two animal
models of lymphoma. A gadolinium (Gd)–labeled den-
drimer nanoparticle (generation-6;f220 kDa/f10 nm)
was injected interstitially into mice bearing hemato-
logic malignancies to perform dynamic micromag-
netic resonance lymphangiography (micro-MRL). Both
a standard T1-weighted 3D fast spoiled gradient echo
and a T2/T1–weighted 3D fast imaging employing
steady-state acquisition (3D-FIESTA-C) were compared
in an imaging study to differentiate intralymphatic
from extralymphatic involvement of tumors. The lym-
phatics and lymph nodes were visualized with both
methods in all cases. In addition, 3D-FIESTA-C de-
picted both the lymphatic system and the extra-
lymphatic tumor. In an animal model, 3D-FIESTA-C
demonstrated that the bulk of the tumor thought to be
intralymphatic was actually extralymphatic. In conclu-
sion, micro-MRL, using Gd-labeled dendrimer nano-
particles with the combined method, can define both
the normal and abnormal lymphatics and can distin-
guish intralymphatic from extralymphatic diseases in
mouse models of malignant lymphoma.
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Introduction
Malignant lymphoma is the fifth leading cause of cancer deaths
in the United States [1]. Extralymphatic disease, which is re-
portedly an important negative prognostic indicator, may alter
the regimen of chemotherapy [2,3]. Animal models are useful in
evaluating new drug and radiation therapies; however, their
validity depends, in part, on the fidelity with which they repro-
duce the characteristics of human lymphomas. It can be dif-
ficult to distinguish nodal tissue from tumor tissue on histology,
and a disease in the vicinity of lymph nodes is often assumed to
be intralymphatic. Conventional imaging methods cannot dif-
ferentiate between intralymphatic and extralymphatic diseases
because they cannot define the normal lymphatic system. No
imaging method is currently available to reliably distinguish if
extralymphatic lymphoma in living mice is in the lymphatic or in
the perilymphatic space. This limitation arises because normal
lymphatic tissue cannot be distinguished from abnormal lym-
phatic tissue. As a result, some animal models of lymphoma
cannot be validated with regard to the presence or absence
of extralymphatic diseases. This raises questions about their
ability to predict tumor behavior in humans.
We have recently developed a micromagnetic resonance
lymphangiography (micro-MRL) method, which employs inter-
stitial injection of a nanoparticulate magnetic resonance im-
aging (MRI) paramagnetic contrast agent, to visualize the
anatomy and physiology of most deep lymphatic vessels and
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lymph nodes [4]. This agent is passively but efficiently taken
up by the lymphatics and readily opacifies draining lymph
nodes. Standard T1-weighted MRI scans clearly demon-
strate both the lymphatic channels and the lymph nodes,
and may be useful for sentinel node imaging with interstitial
injection around the primary cancer [5]. Micro-MRL could
also be useful in characterizing animal models of lymphoma.
In contrast, T2-weighted images, which can be used for
whole-body tumor screening as well as for positron emission
tomography scan [6–13], are useful in depicting the full ex-
tent of diseases, including extralymphatic involvement.
Thus, it would be useful to design a single sequence that si-
multaneously displays the lymphatic system and extra-
lymphatic diseases to fully evaluate the extent of lymphoma.
In the late 1990s, a pulse sequence called True FISP,
which took advantage of faster gradient switching and higher
receiver bandwidth to create a fast scan with signal depen-
dence based on tissue T2/T1 ratio,was developed.As a result,
high-signal structures, such as opacified lymphatics, yield
signals because the shortening of T2 due to the paramagnetic
effects of a gadolinium (Gd)–based contrast agent is less
than the shortening of T1 due to those same agents [14–16].
The nonenhancing tumor is also visualized because the T2
of tumors is usually prolonged compared to that of normal
tissues. Thus, both opacified lymphatics and tumors are
visualized with the contrast-enhanced True FISP method.
The first version of this 3D steady-state coherent imaging
pulse sequence (3D-FIESTA) became available on clinical
MRI instruments in 2001 [14–16]. However, images acquired
with 3D-FIESTA suffered from strong banding artifacts, espe-
cially at the boundaries of air and water. This artifact was
especially noticeable at the surface of the body and at the
spaces adjacent to the gastrointestinal tract [17]. The new
version, 3D fast imaging employing steady-state acquisition
(3D-FIESTA-C), which was introduced in 2003, greatly re-
duced the banding artifacts. Because the image contrast on
3D-FIESTA-C depends on the ratio of the T2/T1 signals, this
sequence has the potential to depict both tumor tissue and
paramagnetic contrast agent with better sensitivity than T1-
weighted sequences alone [17]. Therefore, micro-MRL using
3D-FIESTA-C is potentially able to define the 3D topologic
relationship between the lymphatic system and the tumors.
In this study, we performed micro-MRL with a nanosize
MRI contrast agent, generation-6 (G6), and assessed
T2/T1–weighted 3D-FIESTA-C compared with standard
T1-weighted 3D fast spoiled gradient echo (3D-fSPGR)
MRI in normal mice. Then, to establish if this combined
method might be useful in characterizing and monitoring
mouse models of human lymphoma, we used two mouse
models of hematologic malignancies with intralymphatic and
extralymphatic lesions.
Materials and Methods
Preparation of Paramagnetic Contrast Agent
The G6 polyamidoamine (PAMAM-G6) dendrimer (Den-
dritech, Inc., Midland, MI) has an ethylenediamine core,
256 terminal-reactive amino groups, and a molecular mass
of 58,048 Da. The PAMAM-G6 dendrimer was concen-
trated tof5 mg/ml and diafiltrated against 0.1 M phosphate
buffer at pH 9. The PAMAM-G6 dendrimer was reacted with
a 256-fold molar excess of 2-( p-isothiocyanatobenzyl)-6-
methyl-diethylenetriaminepentaacetic acid (1B4M) [18] at
40jC and maintained at pH 9 with 1 M NaOH for 24 hours.
An additional 256-fold molar excess of 1B4M was added as
a solid after 24 hours. Resulting preparations were purified
by diafiltration using Centricon 30 (Amicon Co., Beverly,
MA). Subsequently, PAMAM-G6 dendrimer–1B4M conju-
gate (f3 mg containing 4 mmol of 1B4M) was mixed with
8 mmol of Gd(III) citrate in 0.3 M citrate buffer overnight at
40jC. Excess Gd(III) was removed by diafiltration using a
Centricon 30 filter (Amicon Co.) while simultaneously chang-
ing the buffer to 0.05 M PBS. The purified sample (G6) was
diluted to 0.2 ml with 0.05 M PBS, and f5 ml was used in
each mouse middle phalange. Quality control was performed
as previously described [19].
Mouse Models
All mouse studies were approved by the Animal Care and
Use Committee of the National Institutes of Health. Ten-
week-old athymic nu/nu mice served as controls (n = 7).
Animal disease models employed were athymic nu/nu mice
bearing a PT-18 xenograft [20], a mast cell lymph node me-
tastasis model (n = 8), and SCID/NOD mice (n = 4; National
Cancer Institute, Frederick, MD) with Karpas 299 anaplastic
large cell lymphoma.
PT-18 cells (107) were injected into the left mammary pad
of athymic nu/nu mice, and 8 of 15 mice developed tumor
masses in the left axillary lymph nodes as well as in the left
mammary gland within 3 weeks.
A lymphoma model of Karpas 299 [21] was created by a
tail vein injection of 2  106 Karpas 299 cells in SCID/NOD
mice. The mice developed one to four extralymphatic soft
tissue tumors by 3 to 5 weeks after the injection of Karpas
299 tumor cells.
Dynamic 3D-Micro-MRL
Mice were anesthetized with an intraperitoneal injection of
1.15 mg of sodium pentobarbital (Dainabot, Osaka, Japan)
and then injected with 0.1 mmol Gd/5 ml G6 contrast agent
directly into the midphalanges of all four extremities, for
a total of four injections. All dynamic micro-MRL images
were obtained using a 1.5-T superconductive magnet (Signa
LX; General Electric Medical System, Waukesha, WI) with a
1-in. round surface coil (birdcage type) fixed to a custom-
constructed coil holder. The mice were wrapped with gauze
to maintain normal body temperature and were placed at
the center of the coils. A 3D-fSPGR (repetition time/echo
time = 14.3/7.0 milliseconds; bandwidth = 31.2 kHz; flip
angle = 30j; four excitations; 36 slice-encoding steps; scan
time = 4 minutes, 23 seconds) with chemical fat suppres-
sion was acquired at 10, 20, 30, and 40 minutes post-
injection of the contrast agent. A 3D-FIESTA-C (Signa LX;
General Electric Medical System) (repetition time/echo
time = 9.1/2.0 milliseconds; bandwidth = 41.7 kHz; flip
Lymph Node Imaging for Hematological Tumors Kobayashi et al. 985
Neoplasia . Vol. 7, No. 11, 2005
angle = 45j; two numbers of excitation; scan time =
2 minutes, 46 seconds) was acquired 15, 25, 35, and
45 minutes postinjection of the contrast agent. The coronal
images were reconstructed with 0.6 mm of section thickness
and 0.3 mm of overlap (two 512 matrix zips). The field of view
was 8  4 cm. The in-plane matrix was 512  256 for 3D-
fSPGR and was 384  256 for 3D-FIESTA-C. The slice data
were processed into 3D images using the maximum intensity
projection method (Advantage Windows; General Electric
Medical System). The image resolution was 156  156 
600 mm for 3D-fSPGR and was 208  312  600 mm for 3D-
FIESTA-C. After imaging, the mice were sacrificed by CO2
inhalation and then dissected to obtain histologic specimens.
To directly compare 3D-fSPGR (T1-weighted) and 3D-
FIESTA-C (T2/T1–weighted) for visualization of the lym-
phatic drainage, serial dynamic micro-MR lymphangiograms
of normal athymic nu/nu mice (n = 7) were obtained with 3D-
fSPGR and 3D-FIESTA-C after injection of the contrast
agent. Images of bilateral axillary and lateral thoracic lymph
nodes and bilateral lymphatic vessels were independently
examined and rated (0–2) by two board-certified radiologists
using the following scoring system: 0 = invisible; 1 = partially
visible; and 2 = completely visible. Any discrepancies be-
tween the two reviewers were resolved by consensus.
To evaluate the topologic relationship between hemato-
logic tumors and the lymphatic system, serial dynamic micro-
MR lymphangiograms of the PT-18 xenograft/lymph node
metastasis model (n = 8) and the systemic Karpas lymphoma
model (n = 4) were acquired with 3D-fSPGR and 3D-FIESTA-
C after injection of the contrast agent, as described above.
Histologic Analysis
After finishing the micro-MRL study, tumors and lymph
nodes around bilateral axillary and lateral thoracic regions
were dissected. Tumors in the neck, thorax, and axilla, and
axillary or lateral thoracic lymph nodes were removed, fixed
in 10% formalin, and stained by hematoxylin–eosin (H–E) to
correlate histology with micro-MRL findings.
Statistical Analysis
A Kruskal-Wallis test with Bonferroni-Dunn correction was
used for the analysis of the visualization of lymph nodes and
lymphatic vessels. All tests were two-sided, andP < .005 was
considered significant after the Bonferroni-Dunn correction.
Results
3D-FIESTA-C Is Superior to 3D-fSPGR in
Identifying Lymphatics
The 3D-FIESTA-C and 3D-fSPGR methods were com-
pared in normal control mice. Four small lymph nodes, bi-
lateral axillary and lateral thoracic, were visualized equally
well with 3D-fSPGR and 3D-FIESTA-C (Figure 1). How-
ever, based on the ratings of the observers, the lymphatic
vessels connecting the lymph nodes were significantly
better visualized with 3D-FIESTA-C than with 3D-fSPGR at
10 and 40 minutes postinjection (P < .005) (Table 1). The
thin lymphatic ducts were especially well depicted with 3D-
FIESTA-C compared with 3D-fSPGR. Thus, the 3D-FIESTA-C
method was more sensitive than 3D-fSPGR in visualizing
the lymphatic system.
3D-FIESTA-C Is Superior to 3D-fSPGR in Visualizing the
Relationship between Tumors and the Lymphatic System
The 3D-FIESTA-C and 3D-fSPGR methods were com-
pared in mice bearing Karpas 299 lymphoma (systemic;
Figure 2, a and b) and PT-18 (xenograft/metastasis; Figure 2,
c and d ). The best imaging time, based on the greatest en-
hancement of normal lymph node tissues for both methods,
to demonstrate metastatic nodules was at 20 or 30 minutes
postinjection of the G6 agent. As previously demonstrated,
the lymphatic system was well depicted on 3D-fSPGR
images (Figure 2, a and c) [5]. However, contrast-enhanced
3D-FIESTA-C (Figure 2, b and d ) not only demonstrated the
lymphatics, but also identified the extralymphatic extension of
Figure 1. Micro-MRL obtained with 3D-FIESTA-C demonstrates better
visualization of the normal lymphatic flow than micro-MRL acquired with
3D-fSPGR. MRL images of the upper body of a mouse with 3D-fSPGR (a;
animation 1) and 3D-FIESTA-C (b; animation 2), which were serially obtained
at 10 minutes postinjection of the G6 contrast agent, are shown from a
series of 3D dynamic micro-MR lymphangiograms. 3D-FIESTA-C especially
showed the connection of thinner lymphatic vessels (arrows) between lymph
nodes better than 3D-fSPGR. Arrowheads indicate injection sites. Broken ar-
rows on (b) indicate the gall bladder.
Table 1. Visualization Score of Four Lymph Nodes and Lymphatic Vessels
on the Upper Body (n = 7).
Time (min)
10 20 30 40
3D-fSPGR lymph nodes 13 14 14 14
3D-FIESTA-C lymph nodes 14 14 14 14
3D-fSPGR lymphatic vessels 6 9 8 7
3D-FIESTA-C lymphatic vessels 8* 10 9 9*
Each score is the sum of consensus-based ratings (performed by two
readers) for seven mice, with higher scores representing better visualization.
*P < 0.005 compared with 3D-fSPGR.
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the Karpas 299 and PT-18 tumors. In the Karpas 299 lym-
phoma model, contrast-enhanced 3D-FIESTA-C simulta-
neously identified the normal lymphatic system as high-signal
structures and the extralymphatic tumors as moderate signal
structures, compared to background. Therefore, the contrast-
enhanced 3D-FIESTA-C method was able to demonstrate
both the normal lymphatics and their relationship to extra-
lymphatic tumors (Figure 2b). In contrast, in the PT-18 tumor
model, the contrast-enhanced 3D-FIESTA-C method demon-
strated that tumors were confined within the lymphatic system
and appeared as filling defects within the nodes (Figure 2d ).
These findingswere confirmed by histologic analysis, as shown
below (Figure 3). In addition, the combination of these two
methods enabled the evaluation of cystic dilatation of lym-
phatics in the lymph node due to tumor metastasis, blockage
of normal lymph flow, and the absence of lymphatic flow in
cystic structures (Figure 3).
Histologic Analysis
In mice bearing Karpas 299, 11 of 13 tumors adhered to
adjacent muscles, blood vessels, or bones. Bilateral axillary
and lateral thoracic lymph nodes of normal sizes, which were
Figure 2. 3D-micro-MR lymphangiograms with 3D-FIESTA-C visualized the relationship between the lymphatic system and tumors in mice. Two series of 3D
dynamic micro-MR lymphangiograms of mice with Karpas 299 tumors (a and b; animation 3 and 4) and PT-18 tumors (c and d; animations 5 and 6) obtained with
repeated 3D-fSPGR (a and c) and 3D-FIESTA-C scans (b and d) at 20 and 25 minutes postinjection of the G6 contrast agent. On micro-MR lymphangiograms with
3D-FIESTA-C, a normal lymphatic system is depicted and is superimposed on Karpas 299 tumors (arrows) (b). In contrast, in a mouse with PT-18, the opacified
normal lymphatic tissue fills in around intranodal metastasis (d).
Lymph Node Imaging for Hematological Tumors Kobayashi et al. 987
Neoplasia . Vol. 7, No. 11, 2005
adjacent to Karpas 299 tumors at the sites where micro-MRL
was indicated, were separately identified. All lymph nodes
were normal on H–E staining (Figure 3). In contrast, in mice
bearing PT-18 xenografts in bilateral mammary glands,
tumors were found in bilateral mammary glands in all eight
mice examined. Additional tumors were found at the site of
bilateral axillary lymph nodes (n = 16) and on either side of
the lateral thoracic lymph node (n = 12). When PT-18 tumors
involved lymph nodes, the lymph nodes were visibly changed
in shape and were clearly depicted by micro-MRL. All
enlarged lymph nodes showed a massive infiltration of
eosinophilic PT-18 cells on specimens stained with H–E
(Figure 3). In addition, 4 of 16 PT-18 tumors in the axillary
lymph nodes contained single or multilocular cystic struc-
tures that were almost always lined by PT-18 cells [Figures 2
(c and d ) and 3]. The existence of all four cystic lesions can
be predicted by the combination of micro-MR lymphangio-
grams taken with 3D-fSPGR or 3D-FIESTA-C.
Discussion
Improvement in the outcome ofmalignant lymphomahasbeen
a remarkable success story in hematology, but lymphoma
remains a significant cause of morbidity and mortality. More-
over, the incidence of lymphoma has been increasing by 4%
per year for the past four decades [1]. Accurate animal models
present an opportunity to test new drug combinations, tar-
geted therapies, and multimodal treatment combinations.
Figure 2. (continued)
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For an animal model to be predictive, it must reflect the
characteristics of its human counterpart. Although most
lymphomas are intralymphatic, an undefined portion is extra-
lymphatic, and patients with extralymphatic lymphoma have
a poorer response to therapy and, therefore, have poorer
prognosis [3]. To emphasize its importance, lymphomas
affecting tissues outside the lymph system (‘‘extra(lymph)-
nodal’’) have ‘‘E’’ added to their stage (e.g., stage IIE) [2]. No
imaging method currently in widespread use can reliably
determine whether a tumor is growing within or outside the
lymph nodes because normal lymphatic vessels and normal
lymph nodes cannot be easily visualized using conventional
imaging modalities. Although a few mouse models of lym-
phoma are available, no method that can be used to deter-
mine if diseases are intralymphatic or extralymphatic exists.
This is critical to the predictive value of animal models.
Micro-MRL enables the visualization of the lymphatic
system and is able to identify intralymphatic diseases by
demonstrating the absence of signal intensity within nodes.
Extralymphatic diseases can be simultaneously distin-
guished from intralymphatic diseases and normal lymphatics
using the 3D-FIESTA-C sequence. Indeed, it was initially
thought that Karpas 299 tumors formed bulky lymphade-
nopathy until it became clear by micro-MRL that the disease
was actually extralymphatic. By accurately mapping the
lymphatic system with micro-MRL, Karpas 299 tumors de-
veloping in the soft tissues and muscles and outside the
lymphatic system were readily diagnosed and confirmed
by histologic analysis (Figure 3). Tumors and normal-sized
lymph nodes were separately obtained by dissection of
mice bearing Karpas 299. The lymph nodes near the tumor
were totally intact, as shown in Figure 3. In contrast, the
PT-18 model demonstrated intralymphatic metastases but
also developed intranodal cystic masses that were easily
detected by micro-MRL. Intranodal lymphoceles are an un-
common feature of human lymphomas. Therefore, micro-
MRL is a useful analytic tool for characterizing animal
models of lymphoma.
The 3D-FIESTA-C method enabled direct visualization
of tumors with T2 prolongation of the tumor tissue while
still depicting enhanced lymphatics and normal nodal tis-
sues. Unlike 3D-FIESTA-C, contrast-enhanced T1-weighted
3D-fSPGR sequence could not directly depict tumors, unless
the tumor had peripheral enhancement provided by the G6
agent through lymphatics. Both noncontrast and contrast-
enhanced 3D-FIESTA-Cmethods depicted cystic masses as
high-signal lesions [17]. Cystic masses can be misdiagnosed
as dilated lymphatic vessels if only 3D-FIESTA-C is
employed. In contrast, contrast-enhanced 3D-fSPGR with
G6 agent can detect the lymphatic flow within cystic struc-
tures, thus indicating their identity as parts of the lymphatic
system (Figure 2c).
A number of imaging methods are used for lymph node
diseases, but they cannot distinguish between intralymphatic
and extralymphatic metastases even in humans. Detection
of lymphoma lesions using nuclear medicine techniques,
especially 18fluoro-D-glucose [22,23] and lymphoscintigraphy
[24,25], is successfully used clinically. However, all nuclear
medicine techniques have insufficient resolution to accu-
rately define the internal anatomy of lymph nodes or lym-
phatic vessels. X-ray lymphangiography using lipiodol, which
is capable of visualizing the lymphatics, is no longer routinely
Figure 3. Histologic analyses revealed the growth of PT-18 tumors in lymph nodes, which received lymphatic flow from the primary site. 3D-micro-MR
lymphangiograms of axillary lymph nodes in a mouse bearing Karpas 299 tumor (a) and PT-18 metastatic tumors (b and c) are shown with histology (H–E staining,
20). The axillary lymph nodes in a mouse bearing Karpas 299 tumor are shown in a normal lymph node without metastasis. We noticed this subtle inhomogeneity
in all normal lymph nodes possibly because of the location of the lymphatic orifice, from which the contrast agent came into the lymph nodes. This inhomogeneity
was clearer in earlier time points and was less clear in later time points. The lymph node tissue with metastatic tumor cells was not enhanced (b). The lymphatic
vessels with multilocular cystic dilatation in the lymph node, which were depicted on micro-MRL, were demonstrated by histology (c). The walls of the cystic
structures were lined by PT-18 tumor cells.
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performed because of difficulty in canulating the lymphatics
in the foot, difficulties in interpreting results, and potential
complications [26–29]. All of these methods are not avail-
able in mouse models because of insufficient spatial reso-
lution. MR lymphography with ultra small particles of iron
oxide might become a useful method in mouse models. To
circumvent these shortcomings, we and others have re-
cently developed MR lymphangiography, which has 10-fold
greater spatial resolution (1 vs 10 mm) and 10-fold greater
temporal resolution than lymphoscintigraphy [4,5,30]. This
new imaging method relies on the selective uptake of Gd-
labeled dendrimer nanoparticles (approximately 10 nm in
diameter) within the lymphatic system [31]. In our previous
studies, imaging was performed with T1-weighted pulse
sequences to take advantage of the T1 shortening afforded
by paramagnetic Gd to visualize the functional anatomy of
lymphatic system [4,5].
Our results suggest that this new micro-MRL method may
be of value not only as a new imaging method, but also as a
platform technology for drug delivery to lymphomas. Intra-
lymphatic treatments are difficult to justify because of uncer-
tainty regarding the delivery of the agent and the systemic
nature of the disease. This method clearly demonstrates
that the lymphatic system allows assessment of pharma-
cokinetics within the lymph nodes and could potentially be
used to deliver activatable therapeutic agents to targeted
lymph nodes.
This method has several limitations. Because intra-
lymphatic metastases may obstruct lymphatic flow, thus
leading to the development of collateral lymphatics [31],
micro-MRLmight be limited in such cases. However, because
micro-MRL is still able to depict the afferent and collateral
lymphatic flows into the metastasized lymph node, it is un-
likely that the method would fail to opacify a node due to
lymphatic obstruction [31]. In reality, as previously demon-
strated, in a spontaneous lymphoma model [4] and in the
PT-18 model herein, complete blockade of lymphatic flow
rarely occurs in lymph nodes involved in hematologic tumors.
In both cases, all lymph nodes were stained well with nano-
size agents (G6 or G8) despite intralymphatic diseases.
Another limitation is that the high-signal intensity asso-
ciated with extralymphatic tumors in FIESTA-C is nonspe-
cific and inflammatory lymph nodes might also have the
same appearance.
Themicro-MRLwith the G6 agent can differentiate normal
from abnormal lymph nodes and also neoplastic from infec-
tious lymph nodes [4]. However, reactive enlargement of
lymph nodes by inflammation might not be easily differenti-
ated from hematologic malignancy because of similarity in
histology. In addition, because micro-MRL with the G6 agent
enhances normal lymph node tissues rather than tumor
nodules, a large lymphoid follicle may be misdiagnosed as
a small tumor nodule. The minimum size of a metastatic
tumor nodule that can be detected by the micro-MRL with the
G6 agent is under investigation using several different tumor
models, including cancers and hematologic malignancies.
In conclusion, we have developed a method of dynamic
micro-MRL based on a combination of interstitial injection of
G6 Gd-labeled dendrimer nanoparticle and dynamic micro-
MRL using 3D-FIESTA-C and 3D-fSPGR. The micro-MRL
using 3D-FIESTA-C is generally sufficient to analyze lym-
phatic tumors. However, only if there are cystic foci in the
tumors will 3D-fSPGR contribute to obtaining additional
information. The method is capable of displaying the func-
tional anatomy of the lymphatic system in a 3D display. The
high spatial and temporal resolutions of this method make
it potentially superior to conventional methods in terms of
lymphatic imaging, which is used to determine whether a
lymphoma is growing within or outside the lymphatic system.
This could lead to a more accurate characterization of animal
models of lymphoma and potentially a more accurate local-
ization of diseases in patients with lymphoma.
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